Mark R. Pittelkow, M.D.

Closed for Enrollment

• A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum Scottsdale/Phoenix, Ariz.

  The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers

• A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Scottsdale/Phoenix, Ariz.

  The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).

• Clinical and Pathologic Studies in Scleromyxedema Rochester, Minn.

  This study is being conducted in order to better understand the biology of scleromyxedema in hope of discovering markers that might give diagnostic and prognostic information, as well as potentially developing more effective therapies in the future.

• Parkinson's Disease iPS Cell Line Research Consortium Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  This study is being done to collect skin samples from people with and without neurodegenerative and vascular disorders including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), stroke and many others. We will use these skin samples to make and bank (store) a group of cells (cell line) called inducible pluripotent stem (iPS) cells.